Evidence map›Paper›PMID 28919784›Full record

ArticleOncoTargets and therapy2017

Durable complete remission of poor performance status metastatic lung adenocarcinoma patient treated with second-line erlotinib: a case report.

Dragana Jovanovic, Ruza Stevic, Marta Velinovic, Milica Kontic, Dragana Maric, Jelena Spasic, Davorin Radosavljevic

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Outcomes of Patients withCancer management and research · 2022
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Dragana JovanovicFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Ruza StevicFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Marta VelinovicUniversity Hospital of Pulmonology, Clinical Center of Serbia, Belgrade, Serbia.
Milica KonticFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Dragana MaricFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Jelena SpasicInstitute for Oncology and Radiology of Serbia, Belgrade, Serbia.
Davorin RadosavljevicInstitute for Oncology and Radiology of Serbia, Belgrade, Serbia.
Centar za Promociju Nauke · RSUniversity of Belgrade · RSOncology Institute of Vojvodina · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This paper presents a rare case of an elderly patient treated with erlotinib for disseminated lung adenocarcinoma with poor performance status (Eastern Cooperative Oncology Group performance status [PS]3). This treatment led to a long duration of complete remission according to Response Evaluation Criteria in Solid Tumors 1.1 - almost 7 years (81 months) of progression-free survival (PFS) and overall survival (OS) of 10 years by March 2017. The treatment with erlotinib started in September 2008 and it was well tolerated with no adverse effects. Mutation analyses (real-time polymerase chain reaction method) revealed deletion of

Indexed as

durable remissionEGFRerlotinibexon 19 deletionlung adenocarcinoma

Identifiers

PMID28919784
PMCPMC5593392
OpenAlexW2753204454

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.